Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins

US7135477B2 · kind B2 · utility

Assignee

• Elan Pharmaceuticals, Inc. · US

Inventors

• Andrei W. Konradi · Burlingame, US
• Christopher Semko · Fremont, US
• Ying-Zi Xu · South San Francisco, US
• Frank Stappenbeck · Seattle, US
• Brian P. Stupi · Cypress, US
• Jenifer Smith · South San Francisco, US
• Michael A. Pleiss · Sunnyvale, US
• Eugene D. Thorsett · Moss Beach, US

Key dates

• Filing date: May 27, 2003
• Grant date: Nov 14, 2006
• Expiry date: May 27, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds which bind α4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4 integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.